Patient characteristics
| RRMS (n = 20/47) | CIS (n = 27/47) | |||||||
|---|---|---|---|---|---|---|---|---|
| RRMS | Control | MCIS | Control | PCISWOE | Control | PCISWE | Control | |
| No. of subjects | 20 | 20 | 9 | 9 | 9 | 9 | 9 | 9 |
| Mean age at disease onset (yr) | 14.23 | NA | 12.99 | NA | 15.06 | NA | 9.37 | NA |
| Range | 6.6–16.5 | 4.1–17.4 | 13.9–18 | 2.6–15.3 | ||||
| Mean age at the time of MRI (yr) | 15.92 | 15.925 | 13.58 | 13.58 | 15.58 | 15.52 | 9.74 | 9.4 |
| Range | 8.4–18 | 7.7–18 | 4.1–18 | 4–17.5 | 14.5–18 | 13–17 | 2.6–15.8 | 2–15 |
| Female sex (%) | 75% | 77.78% | 66.67% | 55.56% | ||||
| Race | ||||||||
| White | 75% | 77.78% | 66.67% | 44.44% | ||||
| Hispanic | 05% | 00% | 22.22% | 11.11% | ||||
| American black | 15% | 11.11% | 11.11% | 22.22% | ||||
| Asian | 05% | 11.11% | 00% | 11.11% | ||||
| Mean disease duration from 1st Sx to MRI analyzed | 2.11 yr | NA | 0.27 yr | NA | 0.37 yr | NA | 0.1125 yr | NA |
| Mean EDSS | 1.625 | NA | 1.83 | NA | 1.38 | NA | 2.6 | NA |
| No. of patients on DMT at the time of MRI | 15/20 | NA | 00/10 | NA | 02/09 | NA | 00/10 | NA |
| Avonexa | 05/15 | NA | 00/10 | NA | 00/09 | NA | 00/10 | NA |
| Rebifa | 04/15 | NA | 00/10 | NA | 01/09 | NA | 00/10 | NA |
| Copaxoneb | 04/15 | NA | 00/10 | NA | 01/09 | NA | 00/10 | NA |
| Multiple drugs | 02/15 | NA | 00/10 | NA | 00/09 | NA | 00/10 | NA |
| No. of patients on monthly steroids | 05/20 | NA | 00/10 | NA | 00/09 | NA | 00/10 | NA |
| No. of patients on steroids within 1 month of MRI | 05/20 | NA | 06/10 | NA | 02/09 | NA | 10/10 | NA |